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Abstract
Background: Rheumatoid arthritis (RA) is a chronic, inflammatory rheumatic disease with the potential to induce
significant disability. Patients with RA are at increased risk of cardiovascular diseases (CVD). Smokers with RA tend to
experience more pain and fatigue, higher disease activity, more erosive joint destruction and a lower health-related
quality of life (HR-QoL) than non-smokers. It remains to be determined whether these effects can be reduced by
smoking cessation.
This randomised controlled trial (RCT) in patients with RA aims to examine the effect of intensive smoking cessation
intervention (motivational counselling combined with tailored nicotine replacement therapy) versus standard care
on smoking cessation, and consequently on disease activity. Secondary objectives are to explore the effect on flare,
risk factors for CVD, lung function, physical function, HR-QoL, pain and fatigue in patients with RA.
Methods: This will be a multicentre, open label, two arm, parallel group, RCT, including 150 daily smokers with RA,
being in remission or having low-moderate disease activity (DAS28≤ 5.1). The intervention group (n = 75) will receive
five counselling sessions with a trained smoking cessation counsellor based on the principles of motivational counselling.
Furthermore, intervention patients will be offered nicotine replacement therapy tailored to individual needs. Participants
randomised to the control group will receive standard care. The co-primary outcome is a hierarchical endpoint, which will
be evaluated at 3 months follow-up and will include (1) self-reported smoking cessation biochemically validated by exhaled
carbon monoxide and (2) achievement of EULAR clinical response (an improvement in DAS28 of > 0.6). Follow-up visits will
be performed at 3, 6 and 12 months post-intervention.
Discussion: This trial will reveal whether intensive smoking cessation counselling helps smokers with RA to achieve
continuous smoking cessation and whether, as a concomitant benefit, it will reduce their RA disease activity. The trial
aims to generate high quality evidence for the feasibility of a health promotion intervention for smokers with RA.
Trial registration: ClinicalTrials.gov, identifier: NCT02901886. Registered on 10 September 2016. Recruitment status
updated on 10th October 2016.
Keywords: Motivational counselling, Nicotine replacement therapy, Cardiovascular disease, Behavioural change, Clinical
health promotion, Smoking cessation intervention, Health-related quality of life, Tobacco smoking, Flare, Cardiovascular
biomarkers
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
disease with a prevalence of 1% in the general popu-
lation [1]. The onset of RA occurs at all ages, but
most frequently in women aged 50–60 years [2]. The
disease is not curable per se; however, its course can
be improved significantly by use of disease-modifying
anti-rheumatic drugs [3, 4]. All joints may be affected,
but symptoms are most common in hands and feet.
During periods of high disease activity, patients can
experience severe pain and fatigue, which may restrict
social life as well as physical and daily life activities
[4, 5]. Furthermore, patients with RA have a reduced
health-related quality of life (HR-QoL) [6, 7] and are
at increased risk of cardiovascular diseases (CVD),
with a risk comparable to that of patients with dia-
betes mellitus [8]. There is evidence that patients with
RA have a 1.6-fold higher rate of acute myocardial in-
farction and ischemic stroke than patients without
RA [9]. The inflammatory process in RA appears to
be linked to the increased risk of CVD [10].
Smoking is more prevalent among Danish patients with
RA than in the general population. A recent survey re-
ported that 30% of patients with RA were daily smokers
[11] compared to 17% in the general Danish population
[12]. Tobacco smoking is a well-known environmental
risk factor for the development of RA and the association
is well established [5, 10, 13–16]. Furthermore, smoking is
associated with chronic persistent RA [17]. Several studies
suggest that smoking may augment symptoms associated
with RA. Smokers with RA have a tendency to experience
more pain and fatigue, higher disease activity, swifter
radiographic progression and reduced HRQoL than non-
smokers with RA [18–21].
Several strategies are available to support smoking ces-
sation. A Cochrane review indicated that smoking cessa-
tion based on individual behavioural counselling
combined with nicotine replacement therapy (NRT) is the
most effective intervention for long-term smoking cessa-
tion in the general population [22]. The process of behav-
ioural change is a central part of smoking cessation [23],
and includes different stages as described in the Stages of
Change Model [24]. Smokers embarking on smoking ces-
sation will often move back and forth between various
stages [25], which often last several years. Motivational
interviewing has proven to be essential in behavioural
counselling, and has assisted healthy people and those
with chronic diseases to quit smoking [26–28]. Cessation
counselling related to smoking, incorporating the princi-
ples of motivational interviewing, aims to encourage
smokers to reflect on the pros and cons of smoking cessa-
tion and their motivation for, and self-efficacy in regard to,
quitting this habit [29]. There is scarce evidence for the ef-
fect of smoking cessation interventions for patients with
RA [30, 31]. In a non-controlled intervention study, 55 pa-
tients with RA received brief smoking cessation advice
(3–5 minutes) from a rheumatologist followed by 20 mi-
nutes of verbal and written smoking cessation advice from
a nurse [31]. Patients were additionally offered undefined
pharmacological therapy. At 3 months follow-up, self-
reported sustained smoking quit rates were 11.8%, indicat-
ing that smoking cessation among patients with inflam-
matory joint diseases may be achievable. The intervention
that had the highest rate of smoking cessation was the
combination of behavioural intervention and NRT [22];
however, this type of intervention has not been tested in a
randomised controlled trial (RCT) among RA patients.
Hence, an RCT to test such an approach versus standard
care is urgently required for these patients.
Our hypothesis is that an intensive smoking cessation
intervention will contribute to smoking cessation in pa-
tients with RA, which will then mediate a reduction in
disease activity.
Aim
This RCT in patients with RA aims to examine the effect
of intensive smoking cessation intervention (motivational
counselling combined with tailored NRT) versus standard
care on smoking cessation, and consequently on disease
activity. Secondary objectives are to explore the effect on
flare, risk factors for CVD, lung function, physical func-
tion, HR-QoL, pain and fatigue in patients with RA.
Methods/Design
Trial design
The study is an international, multicentre, randomised
trial in which daily smokers with RA in remission or with
low-moderate disease activity ≤ 5.1 DAS28 (Disease Activ-
ity Score based on 28 joints assessment, serum-C-reactive
protein (CRP) and patient’s Global assessment of a visual
analogue scale (VAS)) will be randomised 1:1 to either an
intervention group or to a control group. Patients will be
followed for 58 weeks, including the 6-week intervention
period and at 3, 6 and 12 months into the post-
intervention follow-up period.
Study sites
We will recruit patients from the Center for Rheumatol-
ogy and Spine Diseases, Rigshospitalet, Denmark, and
from the Preventive Cardio-Rheuma Clinic, Department
of Rheumatology, Diakonhjemmet Hospital, Oslo,
Norway.
Characteristics of participants
Inclusion criteria
Patients will be included in the study if they have RA as
defined by the American College of Rheumatology 1987
criteria and/or European League Against Rheumatism
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(EULAR) 2010 criteria [32, 33], are over 18 years of age,
smoking tobacco daily, and are able to understand and
speak Danish or Norwegian, respectively. Furthermore,
for the 3 months prior to inclusion patients need to have
been in clinical remission or low-moderate disease activ-
ity (DAS28 ≤ 5.1) and in stable anti-rheumatic medical
treatment as documented in (1) the DANBIO registry in
Denmark, or (2) the electronic patient journal,
Department of Rheumatology, Diakonhjemmet Hospital,
Oslo, Norway.
Exclusion criteria
Patients will be excluded from the study if they have had
a change of dose or preparation in anti-rheumatic med-
ical treatment within the previous 3 months, or a sched-
uled change in anti-rheumatic medical treatment,
including glucocorticoid injection during the previous
month, are cognitively or otherwise unable to give
informed consent, are pregnant or breastfeeding.
Recruitment, screening and enrolment
Screening for potentially eligible patients at each trial
site will be carried out as follows:
At the Danish sites, potential participants will be
recruited by one of the following methods:
1. The DANBIO database, a nationwide registry
including patients with inflammatory joint diseases
in a longitudinal observational cohort [34], will be
used to identify potential patients. Potential patients
will be identified by using the search terms
“rheumatoid arthritis” AND “smoker” (Fig. 1).
Potentially eligible patients will receive an invitation
to participate in the trial in a letter including written
information about the trial and information about
how the patient was identified in DANBIO. Three to
four days after receiving the letter, the patient will be
contacted by phone by the project manager (IKR)
and invited to attend a meeting with a trained
smoking cessation counsellor at which the trial will
be further explained.
2. At routine visits to the rheumatology outpatient
clinic. Potentially eligible patients will be orally
informed about the trial and will subsequently
receive written participant information.
3. By referral from a physician or nurse from the
rheumatology outpatient clinic. Potentially eligible
patients will be orally informed about the trial and will
subsequently receive written participant information.
The written participant information will contain infor-
mation about the trial, background, objectives, course,
measurements, and potential advantages and disadvan-
tages for the patient. Furthermore, potential risks and
adverse effects will be presented, and it will be stressed
that participation is voluntary. Written informed consent
will be obtained from each patient prior to inclusion in
the trial.
At the Norwegian site, potential participants will be
recruited as follows:
 At routine visits to the Preventive Cardio-Rheuma
Clinic, Department of Rheumatology, Diakonhjemmet
Hospital, Oslo, Norway. The information process will
follow the same procedure as in Denmark.
Excluded patients, and eligible patients who do not
want to participate, will be registered as either (1) not
meeting the inclusion criteria, (2) refused to participate,
or (3) excluded for other reasons.
Power sample size considerations
Smoking cessation
The primary endpoint is a hierarchical outcome, hence an
effect of ‘randomisation to smoking cessation interven-
tion’ on disease activity will be statistically supported only
if there is a statistically significant difference in the num-
ber of participants who quit smoking. We expect (conser-
vatively) that 50% of participants in the intervention
group will achieve continuous smoking cessation 3 months
post-intervention (primary outcome 1a) versus 10% of
participants in the control group [35–37], thus corre-
sponding to a number-needed-to-treat of 1/(0.50 – 0.10)
= 1/0.40 = 2.5 ≈ 3 patients. These proportions lead to a
statistical power of 90% with a total sample size of 52, as-
suming a balanced design. Thus, even with 52 participants
(26 in each group) the trial will have great statistical
strength (90%) for the smoking cessation outcome.
Disease activity
For a comparison of two independent binomial propor-
tions using Pearson’s χ2 statistic with a two-sided signifi-
cance level of 0.05, a sample size of 65 participants per
group will provide a power of at least 90% to detect a
difference between the treatment groups, given an ex-
pected response rate (DAS28 improvement > 0.6) of 40%
in the intervention group versus 15% in the control
group [38, 39]. This corresponds to a number-needed-
to-treat of 1/(0.40 – 0.15) = 1/0.25 = 4 patients.
As some attrition is expected it was decided to include
a total of 150 participants in the trial, randomised 1:1. If
inclusion of 150 participants cannot be reached within
the given timeframe, 98 participants will be sufficient to
achieve a statistical power of 80%.
Randomisation and blinding
Immediately after collecting baseline data using stratified
block randomisation (block size 6–10) participants will
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be randomised to either (1) the intervention group or
(2) the control group. The stratification variables are
trial site and anti-cyclic citrullinated peptide (anti-CCP
status). The allocation sequence is generated using
computer-generated random numbers. Participants will
be informed about their group allocation directly after
randomisation. For participants randomised to the
smoking cessation intervention group, the first interven-
tion meeting will be scheduled as soon as possible, pref-
erably immediately after randomisation. It is not possible
either to blind participants to their allocated interven-
tion or to blind the project nurses performing the inter-
vention. The primary outcomes will be assessed by
blinded assessors and smoking cessation will be self-
reported by participants and validated biochemically.
Intervention and control group
Intervention group
The intervention includes (1) individual motivational
counselling in combination with (2) tailored NRT.
1. Individual motivational counselling
The intervention consists of five individual
motivational counselling sessions, each lasting 20–40
minutes over a period of 6 weeks with a trained
smoking cessation counsellor. The principles of
motivational counselling are based on the
transtheoretical model of change [24]. The smoking
cessation counsellor has also been trained in
motivational counselling techniques specific to this
intervention. Six registered nurses from the
participating centres will provide the intervention.
The Danish nurses have all completed the same
Danish Cancer Society training programme based on
the motivational counselling approach. The
Norwegian nurses are specialised in pulmonary
diseases and use the same counselling approach
taught at the Danish Cancer Society.
The smoking cessation counsellor’s role is to ask,
listen and follow the participants cue and to adapt
formal information to the participant’s motivational
Fig. 1 CONSORT Flow diagram: recruitment, screening and enrolment
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stage. Two tools, the ‘Line’ and the ‘Box’, will be
used in the intervention. The Line is a simple tool to
open the dialogue. It is constructed as a VAS scale
and involves two questions which concern (1) the
importance of smoking cessation and (2) the
participant’s own belief in their capability of
stopping smoking [40]. The Box consists of four
empty squares, which the participant is asked to fill
out. The Box helps the participant reflect and
support the lifestyle change [40].
Each meeting contains different themes. The first
meeting is an introduction to the counselling course
and preparation for smoking cessation, including the
participant’s smoking status and their motivation for
cessation. The second meeting aims to prepare the
participant for the three first days without smoking.
The third meeting aims to help the participant with
issues concerning quitting smoking, including risk
situations, relapse, reward and social network, and
smoking cessation. The fourth meeting includes
maintaining motivation, physical activity, handling of
stress and mood swings. The fifth (final) meeting
includes continuing help with smoking cessation and
preparation for the time after the intervention.
2. NRT
The participants in the intervention group will be
offered NRT free of charge and, if accepted, it will
be tailored individually according to the Fagerström
Test for Nicotine Dependence [41]. Participants will
be able to choose between the NRT products,
including a patch, chewing gum, inhalator or mouth
spray. The participants will note their tobacco and
nicotine replacement consumption in a smoking
diary.
Control group – standard care
The control group will receive the standard treatment
and care in the rheumatology outpatient clinic. Partici-
pants will be encouraged to write a diary describing their
tobacco use during the trial period. If participants in the
control group express an interest in receiving smoking
cessation counselling, they will be informed about muni-
cipal programmes.
Outcome measures
The following outcomes will be assessed by blinded
assessors:
1. Primary outcome: smoking status and DAS28 at
3 months follow-up.We will use the strictest definition
of smoking cessation, i.e. self-reported continuous
cessation, verified by exhaled carbon monoxide.
2. Arterial stiffness, serum lipids (total cholesterol,
high- and low-density lipoprotein cholesterol,
triglycerides) and glycated haemoglobin, blood
pressure, pulse, waist circumference, body weight,
height, lung function by forced expiratory volume
in the first second.
The outcomes of smoking status, FLARE instrument,
physical function by Health Assessment Questionnaire
(HAQ), HR-QoL by SF-36 and EuroQoL 5D, pain by
VAS and fatigue by the Bristol Rheumatoid Arthritis
Fatigue Numeric Rating Scale (BRAF-NRS), will be
self-reported.
Primary outcome measure
The primary endpoint will be measured at 3 months
follow-up (Fig. 2). It is a hierarchical endpoint
comprising (1a) self-reported continuous smoking ces-
sation validated by exhaled carbon monoxide at
3 months follow-up and (1b) EULAR clinical response
(an improvement in DAS28 of > 0.6) at 3 months
follow-up.
Endpoint 1b will be tested only if we identify a sta-
tistically significant increase in the number of inter-
vention participants achieving continuous smoking
cessation at 3 months follow-up. The participants will
need to participate in all five meetings in the inter-
vention in order to complete it.
1a.Smoking status
The participants’ smoking status will be
monitored by self-reported continuous smoking
cessation validated by exhaled carbon monoxide
in breath (CO-Check, NEOMED GmbH;
Germany). Carbon monoxide values > 10 ppm
indicate tobacco smoking [42].
1b.Disease activity
The recommended EULAR clinical response in
relation to disease activity will be assessed using
DAS28 at 3 months post-intervention [39]. The
DAS28 score consists of four elements; CRP,
number of swollen joints, number of painful joints
(maximum 28) and a Global General Health VAS
score [43, 44]. The joint count and Global
General Health are assessed by both the
participant and a project nurse blinded to group
allocation.
Secondary outcome measurements
All secondary outcomes are assessed at 3 months
(18 weeks post-intervention), 6 months (30 weeks post-
intervention) and 12 months follow-up (58 weeks post-
intervention).
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Fig. 2 SPIRIT figure
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Smoking status
Smoking status will be monitored by self-reported con-
tinuous smoking cessation and biochemically validated
by exhaled carbon monoxide. Continuous smoking ces-
sation will be measured by asking the patients who re-
port 7-day point prevalence (7 day timeline follow-back)
how many days they have not been smoking. Smoking
status information is self-reported by the participant and
documented in the smoking diary at 3 months post
intervention (week 18). To be grouped as having
‘stopped smoking’ both self-reported and biochemical
analysis should indicate this.
Disease activity
Disease activity will be registered by DAS28, as described
above.
Flare
Participants will be asked to answer the Flare Instru-
ment, which is a patient self-assessment questionnaire
for detecting changes in disease activity among patients
with RA [45], designed to detect both past and present
disease activity. The questionnaire consists of 12 ques-
tions answered on a Likert scale (0 = completely agree,
10 = completely disagree), where higher scores (>2.5) in-
dicate a flare [46]. The Flare Instrument has been trans-
lated into Danish and validated [47].
Cardiovascular disease risk factors
 Blood pressure (mmHg) and heart rate (beats/min)
will be measured after 5 minutes of rest (supine
position) (Mobil-O-Graph, IEM; Germany). If it
exceeds 140/90 mmHg, two additional
measurements will be performed and the mean of
the last two will be registered.
 Arterial stiffness will be measured by pulse wave
velocity (Mobil-O-Graph, IEM; Germany), where a
high value is defined as > 9.9 m/s
 Serum lipids (total cholesterol, high- and low-
density lipoprotein cholesterol, triglycerides) and
glycated haemoglobin will be measured in venous
blood samples
 Waist circumference will be evaluated by a tape
measure in centimetres while the patient is standing.
For women with a waist circumference > 80 cm
there is an increased risk of CVD while the risk is
further increased for waist circumference > 88 cm.
For men, the measures are defined as > 94 cm and >
102 cm, for increased and further increased risk of
CVD, respectively.
 Body weight will be measured to the nearest 0.1 kg
(with ordinary clothes, but without shoes) (OBH
Nordica, Slim Light, 150 kg, Taastrup, Denmark).
 Height will be measured to the nearest centimetre
by a tape measure (without shoes).
Lung function
Forced expiratory volume in the first second will be
measured with a spirometer (EasyOneTM, Model 2001
diagnostic Spirometer, Model 2010 Cradle, NDD Medi-
zintechnik AG; Switzerland).
Physical function
HAQ is a standardised questionnaire to assess disability
and physical function in patients with RA [48]. The in-
strument contains 20 items with four possible answers
in eight categories, namely dressing, rising from a seat,
eating, walking, personal hygiene, stretching for an ob-
ject, grabbing an object and everyday activities. The
questionnaire also includes VAS scales for pain, fatigue
and general health. In DANBIO, five additional ques-
tions have been added with four possible answers related
to physical function, sleep, anxiety and depression. In
this study, we will use the 25 questions as used in
DANBIO.
HR-QoL
HR-QoL is measured using the following two
questionnaires:
 SF-36 is a generic instrument measuring HR-QoL by
36 items on eight scales [49]. The scales are physical
function, physical activity, limitations, pain, general
health, vitality, social function, emotional activity
limitations and mental health, and are summarised
in two summary scales, namely (1) the physical
component scale and (2) the mental component
scale.
 EQ-5D is a generic instrument for measuring HR-
QoL [50]. The questionnaire contains five items
(movement, personal care, usual activities, pain and
anxiety/depression) each with five possible ratings.
Pain
Pain related to RA is self-reported by participants using
the VAS [51]. Participants rate their subjectively experi-
enced level of pain from 0 to 10, where 0 represents ‘no
pain’ and 10 represents the ‘worst imaginable pain’. The
scale is included in HAQ.
Fatigue
The BRAF-NRS assesses fatigue in patients with RA
[52]. It includes three questions concerning fatigue
(level, effect and coping) over the previous 7 days.
Participants rate fatigue on a scale from 0 to 10, where 0
represents ‘no fatigue’ and 10 represents the ‘worst
fatigue’.
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Additional information
We will retrieve data from the DANBIO database re-
garding the participants’ pharmacological treatment,
duration of RA, CRP levels, IgM rheumatoid factor and
anti-CCP status. Additional descriptive data include par-
ticipants’ demography, socioeconomic status, lifestyle
(smoking and alcohol) and consumption of pain killers
obtained via a questionnaire. Co-morbidities are assessed
using the Charlson’s Co-morbidity Scale obtained from
the electronic patient journal.
Translation
The questionnaires Flare Instrument and BRAF-NRS
have been translated from Danish to Norwegian and
back translated from Norwegian to Danish [53]. Further-
more, questions regarding demography, socioeconomic
status, lifestyle (smoking and alcohol) and consumption
of pain killers have been through same translation
process as described above.
Participant timeline
Participants will be followed for 58 weeks, including the
6-week intervention period and a 12 months post-
intervention follow-up period.
Data collection
Data will be collected four times during the trial, namely
at baseline and 3, 6 and 12 months post-intervention.
All participant-reported questionnaires will be com-
pleted electronically on a tablet connected to DANBIO,
which will be used only for participants in the trial.
Blood samples will be destroyed immediately after the
analyses are performed.
Data management
On each study site participants will receive a trial identi-
fication number and all data will be de-identified. The
identification list with participant information and trial
study number will be kept separate and locked away
from the tablet used in the study. De-identified data will
be electronically transferred using an online interface via
a tablet.
Statistical analysis
The primary data analysis will be based on the
intention-to-treat population. This infers that analyses
will be performed on data from all participants disre-
garding any possible drop-out after randomisation. Miss-
ing data among the intention-to-treat population will
initially be imputed using the baseline observation car-
ried forward technique [54]. This simplistic ‘null re-
sponder imputation’ represents our base case, and is
likely valid even if data is ‘missing not at random’ [55] as
it assumes and implies that the patients have had no
improvement (or worsening) since entering the study
(e.g. still smoking with the same disease activity). Fur-
thermore, drop-out analyses will be performed on the
patients lost to follow-up.
Continuous outcomes will be analysed using analysis
of covariance, adjusting for the variable at baseline and
stratifying factors (hospital and anti-CCP status). Cat-
egorical data will be analysed using logistic regression;
the same covariates will be used for both continuous
and categorical data. Statistical significance will be de-
fined as a two-sided P value < 0.05, and will follow the
logic outlined in this protocol.
Multiple sensitivity analyses will be performed to assess
the robustness of the primary analyses, including analyses
based on the ‘as observed population’, repeated measures
and multiple-imputation analyses, which are all based on
model-based approaches for missing data (these details
will be available in the final Statistical Analysis Plan).
Monitoring
Ethics, confidentiality and dissemination
The trial will be performed in accordance with the Helsinki
Declaration. The project has been approved by The Re-
gional Committee on Health Research Ethics (H-16022001)
and the Danish Data Protection Agency (I-suite number
04849). The trial has been reported to Clinicaltrials.gov
(NCT02901886). All data and information collected during
the trial will be kept confidential and in accordance with
the requirements of the Danish and Norwegian Data Pro-
tection Agencies and Good Clinical Practice. We plan to
publish at least three scientific papers in peer-reviewed
journals based on the trial and to disseminate the results to
patient organisations and the public through printed and
electronic media.
The protocol for this randomised trial is reported in
compliance with the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) guidelines
[56] (Additional file 1).
Patient research partner
A patient research partner has been involved in this re-
search trial as recommended by EULAR [57]. We have
involved a patient with RA, who is a former smoker. She
stopped smoking after being diagnosed with RA and has
been involved in the design and final decisions regarding
trial outcomes as well as feedback on instruments and
questionnaires. The patient research partner has read,
commented on and approved the participant informa-
tion for this trial. Furthermore, she will contribute to the
trial with discussion and communication of its results.
Access to data
Data will be encrypted and belong to the Center for
Rheumatology and Spine Diseases, Rigshospitalet, Glostrup,
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Denmark. IKR will analyse the data in collaboration with
the other authors.
Discussion
This trial protocol describes the design of an RCT exam-
ining the effect of an intensive smoking cessation inter-
vention versus standard care on both smoking cessation
and disease activity in smokers with RA. To our know-
ledge, this is the first RCT in this field.
Current evidence suggests that intensive smoking cessa-
tion interventions combining motivational counselling, a
teaching programme and NRT achieve the highest long-
term smoking cessation rates [22]. Evidence shows that
these interventions nearly triple smoking cessation rates
compared to smokers attempting to quit without any kind
of support [22]. Intensive interventions combining these
components also appear the most effective for smokers
with chronic diseases [27]. Among smokers with RA there
might potentially be a great number of heavy smokers
(more than 15 cigarettes per day) [58]. Furthermore, these
smokers might have started smoking in their adolescence
[58]. There is evidence that motivational interviewing com-
bined with NRT is also effective in heavy smokers and not
just in those who smoke less than 15 cigarettes per day. We
therefore hypothesise that the intervention in this trial will
prove effective for smoking cessation in patients with RA.
Some studies suggest that smokers with RA have a
higher need for disease-modifying anti-rheumatic drugs
[59, 60]. In addition, they have a poorer response to anti-
tumour necrosis factor treatment [61] and have an in-
creased risk of CVD. The mechanisms causing the in-
creased risk are unclear; however, the systemic
inflammation and well-known CVD risk factors, such as
smoking and high cholesterol levels, could have an influ-
ence [8, 62, 63]. All this indicates that smokers with RA
could benefit from smoking cessation in regard to their
anti-rheumatic medical treatment, which in most patients
is lifelong, as well as reducing their risk of CVD events.
This trial will include patients with RA; hence, the study
population has the potential to be homogeneous, which
increases the reliability between the different study cen-
tres. Further strengths of the trial are the randomised de-
sign with blinded assessment of the primary outcome
disease activity, which limits the risk of detection bias
[64]. A potential limitation of the trial is lack of blinding
of participants and staff, thus increasing the risk of per-
formance bias. Furthermore, although self-reported smok-
ing cessation is biochemically validated by exhaled carbon
monoxide, it should be noted that carbon monoxide levels
reach near-normalisation after a 12-hour period of smok-
ing cessation. Participants may therefore self-report smok-
ing cessation and present with normal levels of exhaled
carbon monoxide despite having smoked recently [65].
Furthermore, it may be expected that some participants in
the control group will be motivated to stop smoking
merely due to their participation in the trial; this may po-
tentially limit any incremental effect of the smoking cessa-
tion intervention. The included patients’ disease activity
will be low or medium and may not achieve a clinically
significant change in DAS28. Hence, the risk for type II
error will increase.
In conclusion, this trial protocol describes the design
of an RCT which aims to examine whether intensive
smoking cessation intervention may help smokers with
RA to achieve continuous smoking cessation and, sec-
ondly, reduce RA disease activity. The trial is clinically
important as it aims to generate high quality evidence
for the effect of clinical health promotion for smokers
with RA. We expect that the results of the trial may be
generalisable to other patient groups with chronic in-
flammatory diseases.
Trial status
Recruitment for the trial started in October 2016 and is
expected to be completed in October 2018.
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